Literature DB >> 25935915

Rare adverse effect of a common drug: nitrofurantoin-induced ANCA-associated vasculitis.

Abhishek Agarwal1, Abhinav Agrawal2, Karim Nathan3, Satyajeet Roy3.   

Abstract

Nitrofurantoin is commonly prescribed to treat urinary tract infections (UTI). Reported adverse effects include gastrointestinal, pulmonary, hepatic and neurological disorders. We report a case of a 67-year-old woman treated for UTI with nitrofurantoin who presented with antineutrophilic cytoplasmic antibody (ANCA)-associated renal and skin vasculitis 3 days after starting treatment. The symptoms resolved following withdrawal of the drug and treatment with steroids. This is the first reported case of nitrofurantoin causing ANCA-associated vasculitis. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25935915      PMCID: PMC4434272          DOI: 10.1136/bcr-2014-209253

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies.

Authors:  H K Choi; P A Merkel; A M Walker; J L Niles
Journal:  Arthritis Rheum       Date:  2000-02

2.  Tubulointerstitial nephritis with anti-neutrophil cytoplasmic antibody following indomethacin treatment.

Authors:  N Sakai; T Wada; M Shimizu; C Segawa; K Furuichi; K i Kobayashi; H Yokoyama
Journal:  Nephrol Dial Transplant       Date:  1999-11       Impact factor: 5.992

3.  A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection.

Authors:  A Iravani; I Klimberg; C Briefer; C Munera; S F Kowalsky; R M Echols
Journal:  J Antimicrob Chemother       Date:  1999-03       Impact factor: 5.790

Review 4.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

Authors:  Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

5.  Cephotaxime-associated allergic interstitial nephritis and MPO-ANCA positive vasculitis.

Authors:  S Feriozzi; A O Muda; V Gomes; M Montanaro; T Faraggiana; E Ancarani
Journal:  Ren Fail       Date:  2000-03       Impact factor: 2.606

6.  Acute granulomatous interstitial nephritis due to nitrofurantoin.

Authors:  Z Korzets; A Elis; J Bernheim; J Bernheim
Journal:  Nephrol Dial Transplant       Date:  1994       Impact factor: 5.992

7.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

8.  D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease.

Authors:  Frank Bienaimé; Gaétan Clerbaux; Emmanuelle Plaisier; Béatrice Mougenot; Pierre Ronco; Jean-Philippe Rougier
Journal:  Am J Kidney Dis       Date:  2007-11       Impact factor: 8.860

9.  Acute renal failure from nitrofurantoin-induced acute granulomatous interstitial nephritis.

Authors:  G Namagondlu; S E Low; R Seneviratne; A Banerjee
Journal:  QJM       Date:  2009-10-14

10.  Nitrofurantoin-induced acute, subacute and chronic pulmonary reactions.

Authors:  A R Sovijärvi; M Lemola; B Stenius; J Idänpään-Heikkilä
Journal:  Scand J Respir Dis       Date:  1977
  10 in total
  5 in total

1.  c-ANCA vasculitis after initiation of denosumab.

Authors:  Alexandra Sanchez; Matthew Lozier; Brian Cody Adkinson; Amro Ilaiwy
Journal:  BMJ Case Rep       Date:  2019-03-01

Review 2.  Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Cheng-Hua Weng; Zhi-Chun Liu
Journal:  Chin Med J (Engl)       Date:  2019-12-05       Impact factor: 2.628

Review 3.  [Vasculitides and eosinophilic pulmonary diseases].

Authors:  C Kroegel; M Foerster; S Quickert; H Slevogt; T Neumann
Journal:  Internist (Berl)       Date:  2018-09       Impact factor: 0.834

4.  [Vasculitides and eosinophilic pulmonary diseases].

Authors:  C Kroegel; M Foerster; S Quickert; H Slevogt; T Neumann
Journal:  Z Rheumatol       Date:  2018-12       Impact factor: 1.530

5.  Identification of Novel Environmental Substances Relevant to Pediatric Graves' Disease.

Authors:  Qin Xia; Jingjing Liu; Xu Xu; Wei Gu; Kefeng Gu; Xiuli Chen; Rongrong Xie; Dandan Zhang; Haiying Wu; Hui Sun; Fengyun Wang; Linqi Chen; Ting Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-23       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.